论文部分内容阅读
对于医学界和患者而言,1998年infliximab投入美国市场用于治疗中、重度克罗恩病(Crohn disease,CD)和CD肠瘘是一个重要的里程碑。临床研究和大规模临床试验显示,这一被美国食品和药物管理局(FDA)批准的第一个用于临床治疗CD的生物学制剂有许多特点是我们过去所梦寐以求的,如效果好、起效快、药物传递可靠和副作用少等。这些特点以及内科医师和患者对服用类固醇的极度担心,都支持用infliximab而不是传统的皮质类固醇作为重度CD的一线治疗方法。
For the medical community and patients, the introduction of infliximab into the U.S. market in 1998 for the treatment of moderate-to-severe Crohn disease (CD) and intestinal fistula is a significant milestone. Clinical studies and large-scale clinical trials have shown that the first biological preparation approved for clinical treatment of CD by the US Food and Drug Administration (FDA) has many features that we have been dreaming of Fast, reliable drug delivery and fewer side effects. These characteristics, as well as the extreme concern of physicians and patients about taking steroids, support the first-line treatment of severe CD with infliximab instead of the traditional corticosteroid.